MEK inhibition enhances the response to tyrosine kinase inhibitors in acute myeloid leukemiaMaría Luz Morales, Joaquín Martínez‐López, Miguel Gallardo et al.|Scientific Reports|2019Cited by 32
<scp>CALR</scp> mutations screening should not be studied in splanchnic vein thrombosisNerea Castro, Joaquín Martínez‐López, Inmaculada Rapado et al.|British Journal of Haematology|2015Cited by 15
Use of <scp>S</scp>orafenib as an effective treatment in an <scp>AML</scp> patient carrying a new point mutation affecting the <scp>J</scp>uxtamembrane domain of <i><scp>FLT</scp>3</i>Joaquín Martínez‐López, Rosa Ayala, Nerea Castro et al.|British Journal of Haematology|2012Cited by 5
Wilms Tumor 1 gene expression levels improve risk stratification in <scp>AML</scp> patients. Results of a multicentre study within the Spanish Group for Molecular Biology in HaematologyCarolina Martínez‐Laperche, Mi Kwon, Ana Carolina Franco-Villegas et al.|British Journal of Haematology|2017Cited by 4
Preclinical Evidence That Trametinib Enhances the Response to Tyrosine Kinase Inhibitors in Acute Myeloid LeukemiaJoaquín Martínez‐López, Miguel Quintela-Fandiño, María José Pedraja Linares et al.|Blood|2016Cited by 1